JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will present and host 1×1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.
|Presentation Date:||Wednesday, September 14, 2022|
|Time:||3:30 PM ET|
|Presenter:||Miranda Toledano – CEO|
About Entera Bio
Entera is a leader in the development of orally delivered macromolecules therapeutics including peptides and other therapeutic proteins, for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613 and has a Type C meeting scheduled with FDA with respect to its Phase 3 program in H2 2022. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
Entera Bio: Ms. Miranda Toledano Chief Executive Officer Entera Bio Email: firstname.lastname@example.org Investor Relations: Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 email@example.com Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 firstname.lastname@example.org